Related Experiment Videos
Comments to Drs. Bahji, Vazquez, and Zarate
Wayne C Drevets1, Vanina Popova2, Ella J Daly3
1Neuroscience Clinical Development, Janssen Research & Development, LLC, San Diego, CA, USA.
Journal of Affective Disorders
|February 11, 2021
Summary
Direct head-to-head studies are lacking to compare intranasal esketamine and intravenous ketamine. Current data is insufficient to conclude which ketamine formulation offers superior efficacy due to differing trial designs and patient groups.
Area of Science:
- Pharmacology
- Clinical Trials
- Neuroscience
Background:
- Intranasal esketamine and intravenous ketamine are used for various conditions.
- Direct comparative efficacy data between these two formulations is currently unavailable.
- Existing studies often feature distinct methodologies and patient cohorts.
Discussion:
- The absence of head-to-head trials prevents definitive conclusions on comparative efficacy.
- Variations in study design and patient populations across existing research limit direct comparisons.
- Further research with standardized protocols is needed to ascertain the relative benefits of each administration route.
Key Insights:
- Comparative efficacy of intranasal versus intravenous ketamine remains undetermined.
- Heterogeneity in study designs and patient populations hinders direct evidence-based conclusions.
- Robust clinical trials are essential for establishing treatment guidelines.
Outlook:
- Future research should prioritize head-to-head comparisons of intranasal and intravenous ketamine.
- Standardized trial designs are necessary to yield reliable comparative efficacy data.
- This will inform optimal clinical use and treatment selection for ketamine-based therapies.